You are here: Industry Insights > Akorn

News List

Akorn to Sell Consumer Health Business to Prestige Consumer Healthcare americanpharmaceuticalreview
June 02, 2021
Akorn Operating Company, a leading specialty pharmaceutical company, announced that it has entered into a definitive agreement to sell its Consumer Health business to an affiliate of Prestige Consumer Healthcare Inc. for a total enterprise value of ...
Prestige to acquire Akorn’s consumer product portfolio for $230m pharmaceutical-technology
May 31, 2021
Prestige Consumer Healthcare has agreed to acquire speciality pharmaceutical company Akorn’s Consumer Health unit for a total enterprise value of $230m in cash.
Financial Report: Akorn contractpharma
August 12, 2020
Revenues down 32% in the second quarter.
Akorn Receives Warning Letter from FDA contractpharma
June 27, 2019
Relates to the inspection of its Somerset, NJ manufacturing facility in July and August of 2018.
Third Akorn sterile drug plant hit by FDA as new CEO lays out blueprint for a better future fiercepharma
March 03, 2019
Akorn Pharmaceuticals, which had a $4.3 billion buyout by Fresenius tank last fall, just can’t seem to catch a break.
Akorn Comments on Favorable Court Order firstwordpharma
March 03, 2019
Akorn, Inc. (Nasdaq: AKRX) announced today that the Delaware Court of Chancery has denied a request by Fresenius Kabi AG to bring a fraud claim against Akorn.
Akorn searches for new CEO after failed Fresenius merger pharmaphorum
December 12, 2018
US generics firm Akorn is searching for a new CEO in the wake of a failed merger with Fresenius Kabi last year.Akorn had been set to merge with Fresenius Kabi in 2017...
Delaware Supreme Court allows Fresenius to abandon Akorn acquisition pharmaceutical-technology
December 11, 2018
The Delaware Supreme Court in the US has ruled that German health care company Fresenius could legally back out of its acquisition of US-based Akorn....
Akorn's CEO bows out after failing last-ditch bid to save Fresenius merger fiercepharma
December 11, 2018
Akorn once again tried and failed to salvage its $4.3 billion merger with Fresenius. Delaware's top court ruled that Fresenius had nixed the deal legally after data problems cropped up, and in the wake of the decision, Akorn's CEO made his exit.
US court affirms decision to permit Fresenius to withdraw from deal to buy Akorn firstwordpharma
December 10, 2018
The Delaware Supreme Court on Friday upheld a lower court ruling permitting Fresenius Kabi to terminate its agreement to acquire Akorn for more than $4 billion. Shares in the latter drugmaker were down as much as 37 percent on the news.

Previous page 1 2 Next page